Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
Histiocytic sarcoma is a rare malignant neoplasm that may occur de novo or in the context of a previous hematologic malignancy or mediastinal germ cell tumor. Here, we performed whole exome sequencing and RNA-Seq on twenty-one archival cases of primary histiocytic sarcoma. We identified a high number of genetic alterations within the RAS-RAF-MAPK pathway in 21/21 cases, with alterations in NF1 (6/21), MAP2K1 (5/21), PTPN11 (4/21), BRAF (4/21), KRAS (4/21), NRAS (1/21) and LZTR1 (1/21), including single cases with homozygous deletion of NF1, high-level amplification of PTPN11 and a novel TTYH3-BRAF fusion. Concurrent NF1 and PTPN11 mutations were present in 3/21 cases, and 5/7 cases with alterations in NF1 and/or PTPN11 had disease involving the gastrointestinal tract. Following unsupervised clustering of gene expression data, cases with NF1 and/or PTPN11 abnormalities formed a distinct tumor subgroup. A subset of NF1/PTPN11 wild-type cases had frequent mutations in B-cell lymphoma associated genes and/or clonal IG gene rearrangements. Our findings expand the current understanding of the molecular pathogenesis of this rare tumor and suggest the existence of a distinct subtype of primary histiocytic sarcoma characterized by NF1/PTPN11 alterations with predilection for the gastrointestinal tract.